Article

Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1

2022-09-15

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe COVID-19 among high-risk individuals during the Delta-variant phase. We sought to determine the effectiveness of NMV-r against Omicron lineage variants BA.2/BA2.12.1, and assess for evidence of a clinical rebound effect....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 753a8f80-9242-5f1a-9a9a-235e4ec51688
DOI: 10.1101/2022.09.12.22279866

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1DOI 10.1101/2022.09.12.22279866Read

Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2: A single-center large observational studySemantic proximity Read

Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United StatesSemantic proximity Read

Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)Semantic proximity Read

REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 ResultsSemantic proximity Read

Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron PhaseSemantic proximity Read

<i>In vivo</i> virological efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineagesSemantic proximity Read

Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational studySemantic proximity Read

Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity Read

Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)Semantic proximity Read

REAL-WORLD EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR ON COVID-19-ASSOCIATED HOSPITALIZATION PREVENTION: A POPULATION-BASED COHORT STUDY IN THE PROVINCE OF QUÉBEC, CANADASemantic proximity Read

Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical Progression Treated with Molnupiravir or Nirmatrevir Plus Ritonavir During the Omicron Era in Italy: A Nationwide, Observational StudySemantic proximity Read